Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Coriolus mushroom (also known as Trametes versicolor or turkey tail) has been studied for its potential immune-modulating and anti-cancer properties, primarily due to its polysaccharide constituents, such as polysaccharide-K (PSK) and polysaccharopeptide (PSP). In the context of lymphoma, preclinical studies (in vitro and animal models) suggest that extracts from Coriolus can stimulate immune function and may inhibit the growth of certain cancer cells, including lymphomas. Several clinical trials, mostly conducted in Asia, have examined PSK and PSP as adjuvant therapies in various cancers, but most human data focus on gastrointestinal and breast cancers.

For lymphoma specifically, there is limited direct evidence from randomized controlled trials. Most support comes from small pilot studies, case reports, and extrapolation from broader immune-oncology research. While PSK/PSP have been shown to improve survival and immune function in some cancer patients, robust human data for lymphoma are lacking. International guidelines do not currently recommend Coriolus products as standard therapy for lymphoma, but they may be used as complementary therapy in some settings.

In summary, the use of Coriolus for lymphoma has a scientific basis rooted in laboratory and limited clinical research, but the strength of evidence in humans is low (rated 2 out of 5), and its use should not replace conventional treatments.

More about Coriolus mushroom
More about Lymphoma

Other ingredients used for Lymphoma

Other health conditions supported by Coriolus mushroom

Products containing Coriolus mushroom